Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02877381
Other study ID # 15063007
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 2016
Est. completion date August 1, 2019

Study information

Verified date April 2021
Source Rush University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the optimal dosing regimen and route of administration of tranexamic acid (TXA) [single dose intravenous (IV), double dose intravenous, intravenous + topical, and oral repeated dosing] to minimize post-operative blood loss and transfusion requirements following revision total knee arthroplasty (RTKA).


Description:

Study Design: Prospective randomized control study Scientific Background/Intro: Total hip or knee arthroplasty is associated with the risk of moderate to significant blood loss. Approximately one-third of patients undergoing total joint replacement surgery require one to three units of blood postoperatively. Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used orally, intravenously, and topically to control bleeding after total joint replacement. The use of TXA has been shown to significantly reduce the need for blood products during total joint replacement.1-3 Many studies have explored the use of various TXA regimens following primary TKA. Tanaka et al. demonstrated both that pre-operative administration of TXA was superior to intra-operative administration and that a double dose regimen is superior to a single dose regimen.4 Maniar et al. further supported the idea that pre-operative TXA administration is superior, and the addition of higher doses of TXA improved efficacy without an increase in thromboembolic complications.5 More recently, Lin et al. demonstrated that combining a pre-operative IV dose of TXA with an intra-articular dose after arthrotomy closure was superior to an intra-articular dose alone.6 Also, in an unpublished randomized control trial that we recently completed, we found oral TXA to provide equivalent blood control at a lower cost than IV TXA. It is well known that revision joint arthroplasty cases are more complex than primary joint replacements. Revision total knee arthroplasty is associated with a greater risk of blood loss and increased transfusion rates compared to primary TKA.7 Despite the vast body of literature investigating TXA following primary TKA, only three retrospective studies have been published on the use of TXA after revision TKA.8-10 All three studies have shown that IV TXA decreased both the rate of transfusions and the amount of blood transfused when compared to controls.8-10 Although the TXA formulations used in primary TKA have been shown to be effective in the retrospective studies, the amount of blood loss and risk of transfusion still remains significantly higher than during primary TKA. By performing the first randomized control trial on the use of TXA following revision TKA, we believe it will help change practice patterns by providing evidence that the same TXA formulations used in primary TKA are inadequate for revision TKA. Additionally, we will be exploring new combinations of TXA administration to answer some questions brought up by previous studies in regards to the optimal TXA regimen.


Recruitment information / eligibility

Status Completed
Enrollment 175
Est. completion date August 1, 2019
Est. primary completion date August 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients scheduled for revision THA or TKA defined as femoral component exchange, acetabulum/tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Exclusion Criteria: - Patients scheduled for a head and liner/poly exchange, known allergy to TXA, acquired disturbances of color vision, refusal of blood products, pre-operative use of anticoagulant therapy within five days before surgery, a history of arterial or venous thrombotic disease (including a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA)), pregnancy, breastfeeding, or major co-morbidities (myocardial infarction or stent placement within one year, severe pulmonary disease, renal impairment, or hepatic failure).

Study Design


Intervention

Procedure:
Revision Total Knee Arthroplasty (TKA)
Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
Revision Total Hip Arthroplasty (THA)
Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.

Locations

Country Name City State
United States Rush University Medical Center Chicago Illinois
United States New York University Medical Center New York New York
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Rush University Medical Center Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-operative reduction in Hemoglobin Pre-operative hemoglobin minus the lowest post-operative hemoglobin prior to any transfusion Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Primary Post-operative reduction in Hematocrit Pre-operative hematocrit minus the lowest post-operative hematocrit prior to any transfusion Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Primary Calculated blood loss Based on predicted blood volume and hemoglobin balance Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Primary Number of units transfused per patient Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Primary Number of Patients Transfused Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Secondary Cost-comparison Cost differences resulted from differences in the blood transfusion rate, length of hospital stay, and management of complications as well as from the cost of the TXA itself Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Secondary Deep Vein Thrombosis, Pulmonary Embolus, Cerebrovascular accident or Transient ischemic attack Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Secondary Return to the OR within 30 days; Re-admission within 30 days; Periprosthetic fracture within 30 days Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
Secondary Superficial infection or Deep infection, defined as Synovial White Blood Cell (WBC) count > 4200 WBC/ml or Synovial WBC > 3000 WBC/ml & C-Reactive Protein (CRP) > 10 mg/dl & Erythrocyte Sedimentation Rate (ESR) > 30 mm/hr ; Post-operative and before discharge from hospital (inpatient), < 30 days from surgery
See also
  Status Clinical Trial Phase
Completed NCT05081063 - Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients Phase 3
Completed NCT01370460 - Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty Phase 2
Recruiting NCT05292001 - Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma Phase 4
Withdrawn NCT02138175 - Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective
Completed NCT01683955 - Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty Phase 1
Terminated NCT02762773 - Effect of Non-Dissection of the Inferior Rectus Sheath on Intraoperative Blood Loss N/A